Abstract
Gene therapy is one of the most promising approaches for the treatment of lysosomal storage disorders (LSDs). This is especially true for the 75 % of LSDs that have central nervous system (CNS) involvement, where enzyme replacement therapy (ERT), the standard of care for LSDs, is ineffective in treating the neurological features of these diseases. Recombinant adeno-associated virus (AAV) vectors have emerged as the most efficient and promising gene transfer vehicles for the CNS and in particular for LSDs. Direct infusion of AAV vectors into interconnected structures in the brain has achieved widespread distribution of vector and therapeutic levels of lysosomal enzymes throughout the CNS. Early stages of clinical trials are currently underway for treating neurological disorders with AAV vectors, with much anticipation for moving these treatments forward to aid patients and families affected by these terrible diseases. In this chapter, we will detail the protocols used for stereotaxic AAV infusion into the brain of mice, cats, sheep, and nonhuman primates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arfi A, Richard M, Scherman D (2012) Innovative therapeutic approaches for improving patient life condition with a neurological lysosomal disease. In: Tan Ü (ed) Latest findings in intellectual and developmental disabilities research. Croatia, InTech
Suzuki K (2003) Globoid cell leukodystrophy (Krabbe’s disease): update. J Child Neurol 18:595–603
Sano R et al (2009) GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol Cell 36:500–511
Fuller M, Meikle PJ, Hopwood JJ (2006) Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford
Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta 1455:105–138
Carstea ED et al (1997) Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277:228–231
Meikle PJ et al (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
Byrne BJ et al (2011) Pompe disease gene therapy. Hum Mol Genet 20:R61–R68
Desnick RJ, Schuchman EH (2012) Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 13:307–335
Johnson WG et al (1973) Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. Birth Defects Orig Artic Ser 9:120–124
Enns GM, Huhn SL (2008) Central nervous system therapy for lysosomal storage disorders. Neurosurg Focus 24:E12
Dickson P et al (2007) Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 91:61–68
Lee WC et al (2007) Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J 21:2520–2527
Chang M et al (2008) Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 16:649–656
Hemsley KM et al (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 7:740–753
Dodge JC et al (2009) Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 215:349–357
Hemsley KM et al (2009) Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs: a proof of principle study. Mol Genet Metab 98:383–392
Cabrera-Salazar MA et al (2010) Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Exp Neurol 225:436–444
Ziegler RJ et al (2011) Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion. Exp Neurol 231:261–271
Auclair D et al (2012) Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr Res 71:39–45
Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood–brain barrier. Proc Natl Acad Sci 104:7594–7599
Osborn MJ et al (2008) Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther 16:1459–1466
Papademetriou J et al (2012) Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J Inherit Metab Dis 36:467–477
Boado RJ et al (2008) Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood–brain barrier. Biotechnol Bioeng 99:475–484
Grubb JH et al (2008) Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc Natl Acad Sci 105:8375–8380
Böckenhoff A et al (2014) Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A.J Neurosci 34:3122–3129
Meng Y et al (2014) Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a Peptide that mediates delivery to the brain. Mol Ther 22:547–553
Biffi A et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:6148
Ioannou YA, Bishop DF, Desnick RJ (1992) Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J Cell Biol 119:1137–1150
Neufeld EF (2006) Enzyme replacement therapy: a brief history. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford
Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839–849
Taylor RM, Wolfe JH (1997) Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat Med 3:771–774
Passini MA et al (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 22:6437–6446
Luca T et al (2005) Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol Ther 12:669–679
Hennig AK et al (2003) Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 23:3302–3307
Broekman MLD et al (2009) Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-gangliosidosis brain. Gene Ther 16:303–308
Hennig AK et al (2004) AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther 10:106–116
Griffey M et al (2005) AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther 12:413–421
Liu G et al (2005) Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 25:9321–9327
Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 27:9928–9940
Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537
Salegio EA et al (2013) Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther 20:348–352
Bosch A et al (2000) Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 1:63–70
Skorupa AF et al (1999) Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 160:17–27
Cachon-Gonzalez MB et al (2006) Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci 103:10373–10378
Dodge JC et al (2005) Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci 102:17822–17827
Baek RC et al (2006) AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One 5:e13468
Kells AP et al (2009) Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci 106:2407–2411
Liu G et al (2005) Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther 12:1503–1508
Salegio EA et al (2010) Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther 21:1093–1103
Suzuki Y, Oshima A, Nanba E (2001) b-Galactosidase deficiency(b-Galactosidosis): GM1 Gangliosidosis and Morquio B disease. In: Valle D et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill Companies, Inc., New York, NY
Sango K et al (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11:170–176
Gravel RA et al (2001) The GM2 gangliosidoses. In: Valle D et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill Companies, Inc., New York, NY
Afione SA, Conrad CK, Flotte TR (1995) Gene therapy vectors as drug delivery systems. Clin Pharmacokinet 28:181–189
Ciesielska A et al (2013) Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21:158–166
Franco LM et al (2005) Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12:876–884
Passini MA et al (2007) Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci 104:9505–9510
Bradbury AM et al (2013) Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy. Mol Ther 21:1306–1315
Ciron C et al (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60:204–213
Colle MA et al (2010) Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet 19:147–158
Kügler S et al (2003) Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311:89–95
Lawlor PA et al (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692–1702
Markakis EA et al (2010) Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol Ther 18:588–593
Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583–593
Burger C et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317
Cearley CN et al (2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16:1710–1718
Foust KD et al (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65
Gray SJ et al (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19:1058–1069
Klein RL et al (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13:517–527
Klein RL et al (2008) AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 16:89–96
Sondhi D et al (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 15:481–491
Yang B et al (2012) Intravascular delivery of rAAVrh.8 generates widespreading transduction of neuronal and glial cell types in the adult mouse central nervous system. Molecular Therapy, Philadelphia, PA
Zhang H et al (2011) Several rAAV vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19:1440–1448
Sands MS, Haskins ME (2008) CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 97:22–27
Worgall S et al (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 19:463–474
Ellinwood NM et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251–259
Gray SJ et al (2013) Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20:450–459
Sondhi D et al (2012) Long term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and non-human primates for the treatment of late infantile neuronal lipofuscinosis. Hum Gene Ther Methods 23:324–335
Sanftner LM et al (2005) AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 194:476–483
Salegio EA et al (2012) Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther 23:891–902
Ciron C et al (2009) Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 20:350–360
Cachon-Gonzalez MB et al (2012) Gene transfer corrects acute GM2 gangliosidosis: potential therapeutic contribution of perivascular enzyme flow. Mol Ther 20:1489–1500
Kaplitt MG et al (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8:148–154
Passini MA et al (2003) Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 77:7034–7040
Broekman MLD et al (2006) Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138:501–510
Meijer DH et al (2009) Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 16:664–671
Federici T et al (2012) Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 19:852–859
Rafi MA et al (2005) AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol Ther 11:734–744
Broekman MLD et al (2007) Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol Ther 15:30–37
Wolf DA et al (2011) Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 43:123–133
Baker HJ et al (1971) Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency. Science 174:838–839
Cork LC et al (1977) GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency. Science 196:1014–1017
Martin DR et al (2008) Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis. Mol Genet Metab 94:212–221
Martin DR et al (2004) An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. Exp Neurol 187:30–37
Baek RC et al (2009) Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44:197–205
McCurdy VJ et al (2012) Presymptomatic gene therapy cures feline GM1 gangliosidosis. Molecular Therapy, Philadelphia, PA, USA
Johnson AK et al (2012) Dramatic phenotypic improvement in a feline model of Sandhoff disease treated by adeno-associated virus gene therapy. Molecular Therapy, Philadelphia, PA, USA
http://www.ncbi.nlm.nih.gov/pubmed/25474439
http://www.ncbi.nlm.nih.gov/pubmed/24718858
Johnson AK et al (2011) Dramatic phenotypic improvement after adeno-associated virus gene therapy in a feline model of sandhoff disease. Molecular Therapy, Seattle, WA, USA
Torres PA et al (2010) Tay-Sachs disease in Jacob sheep. Mol Genet Metab 101:357–363
Porter BF et al (2011) Pathology of GM2 gangliosidosis in Jacob sheep. Vet Pathol 48:807–813
Whitlock BK et al (2010) Interaction of kisspeptin and the somatotropic axis. Neuroendocrinology 92:178–188
Bankiewicz KS et al (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2–14
Fiandaca MS et al (2008) Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5:123–127
Kaplitt MG et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369:2097–2105
Eberling JL et al (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980–1983
Bobo RH et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91:2076–2080
van der Bom IMJ et al (2013) Frameless multimodal image guidance of localized convection-enhanced delivery of therapeutics in the brain. J Neurointerv Surg 5:69–72
Yin D et al (2010) Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 113:240–248
White E et al (2011) A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model. J Neurosci Methods 195:78–87
Krauze MT et al (2005) Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Protoc 16:20–26
Subramanian T et al (2005) MRI guidance improves accuracy of stereotaxic targeting for cell transplantation in parkinsonian monkeys. Exp Neurol 193:172–180
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Golebiowski, D. et al. (2015). AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement. In: Bo, X., Verhaagen, J. (eds) Gene Delivery and Therapy for Neurological Disorders. Neuromethods, vol 98. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2306-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2306-9_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2305-2
Online ISBN: 978-1-4939-2306-9
eBook Packages: Springer Protocols